OXiGENE Inc (NASDAQ: OXGN) rose 46.3% to 82 cents, as the company reported that results of its Phase 2 study of CA4P in recurrent ovarian cancer has been published in Journal of Clinical Oncology. The study met primary endpoint of improvement. Share volume was 12.8 million, compared to an all-day average of 150,000
